378 related articles for article (PubMed ID: 20706150)
61. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
62. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study.
Gilger MA; El-Serag HB; Gold BD; Dietrich CL; Tsou V; McDuffie A; Shub MD
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):141-6. PubMed ID: 18664864
[TBL] [Abstract][Full Text] [Related]
63. Clinical and endoscopic evaluation of gastroesophageal reflux disease in patients successfully treated with esomeprazole.
da Silva EP; Nader F; Quilici FA; Eisig JN; Zaterka S; Meneghelli U
Arq Gastroenterol; 2003; 40(4):262-7. PubMed ID: 15264050
[TBL] [Abstract][Full Text] [Related]
64. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.
Lightdale CJ; Schmitt C; Hwang C; Hamelin B
Dig Dis Sci; 2006 May; 51(5):852-7. PubMed ID: 16773434
[TBL] [Abstract][Full Text] [Related]
65. An open non-comparative clinical study for the evaluation of safety and efficacy of esomeprazole in patients of reflux oesophagitis in Indian population.
Dinakaran NH; Rajkumar JS; Potdar NP; Desai A
J Indian Med Assoc; 2002 Oct; 100(10):624-6. PubMed ID: 12452520
[TBL] [Abstract][Full Text] [Related]
66. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
[TBL] [Abstract][Full Text] [Related]
67. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
Pace F; Negrini C; Wiklund I; Rossi C; Savarino V;
Aliment Pharmacol Ther; 2005 Aug; 22(4):349-56. PubMed ID: 16098002
[TBL] [Abstract][Full Text] [Related]
68. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
69. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole.
Sheu BS; Chang WL; Cheng HC; Kao AW; Lu CC
Am J Gastroenterol; 2008 Sep; 103(9):2209-14. PubMed ID: 18702650
[TBL] [Abstract][Full Text] [Related]
70. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
Digestion; 2005; 71(3):152-8. PubMed ID: 15870503
[TBL] [Abstract][Full Text] [Related]
71. Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease.
Junghard O; Wiklund IK
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):555-60. PubMed ID: 17556901
[TBL] [Abstract][Full Text] [Related]
72. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.
Vakil NB; Traxler BM; Levine D
Am J Gastroenterol; 2004 Aug; 99(8):1437-41. PubMed ID: 15307856
[TBL] [Abstract][Full Text] [Related]
73. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.
Laine L; Sugg J
Am J Gastroenterol; 2002 Dec; 97(12):2992-7. PubMed ID: 12492181
[TBL] [Abstract][Full Text] [Related]
74. Esomeprazole magnesium (Nexium).
Baker DE
Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
[TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
[TBL] [Abstract][Full Text] [Related]
76. Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study.
Chand N; Johnson DA; Tabangin M; Ware JC
Aliment Pharmacol Ther; 2004 Nov; 20(9):969-74. PubMed ID: 15521844
[TBL] [Abstract][Full Text] [Related]
77. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Haddad I; Kierkus J; Tron E; Ulmer A; Hu P; Sloan S; Silber S; Leitz G
J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):798-807. PubMed ID: 23863328
[TBL] [Abstract][Full Text] [Related]
78. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
79. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
[TBL] [Abstract][Full Text] [Related]
80. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
